TY - JOUR
T1 - The Impact of IFNλ4 on the Adaptive Immune Response to SARS-CoV-2 Infection
AU - Møhlenberg, Michelle
AU - Monrad, Ida
AU - Vibholm, Line K.
AU - Nielsen, Stine S.F.
AU - Frattari, Giacomo Schmidt
AU - Schleimann, Mariane Høgsbjerg
AU - Olesen, Rikke
AU - Kjolby, Mads
AU - Gunst, Jesper Damsgaard
AU - Søgaard, Ole Schmeltz
AU - O'Brien, Thomas R.
AU - Tolstrup, Martin
AU - Hartmann, Rune
N1 - Funding Information:
The funding source had no role in the study design, collection, analysis, and interpretation of data, writing of the article, or the decision to submit the article for publication. This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/11
Y1 - 2021/11
N2 - Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients.
AB - Genetic polymorphisms at the IFNL4 loci are known to influence the clinical outcome of several different infectious diseases. Best described is the association between the IFNL4 genotype and hepatitis C virus clearance. However, an influence of the IFNL4 genotype on the adaptive immune system was suggested by several studies but never investigated in humans. In this cross-sectional study, we have genotyped 201 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive participants for 3 IFNL4 polymorphisms (rs368234815, rs12979860, and rs117648444) and stratified them according to the IFNλ4 activity. Based on this stratification, we investigated the association between the IFNL4 genotype and the antibody as well as the CD8+ T cell response in the acute phase of the SARS-CoV-2 infection. We observed no differences in the genotype distribution compared with a Danish reference cohort or the 1,000 Genome Project, and we were not able to link the IFNL4 genotype to changes in either the antibody or CD8+ T cell responses of these patients.
KW - antibody
KW - COVID-19
KW - genetics
KW - Interferon lambda-4
KW - SARS-CoV-2
KW - T cell response
UR - http://www.scopus.com/inward/record.url?scp=85119824637&partnerID=8YFLogxK
U2 - 10.1089/jir.2021.0106
DO - 10.1089/jir.2021.0106
M3 - Journal article
C2 - 34788130
AN - SCOPUS:85119824637
SN - 1079-9907
VL - 41
SP - 407
EP - 414
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 11
ER -